Global Biosimilars Market: By Products Type (Monoclonal Antibodies, Recombinant Hormones, Recombinant Growth Factors, Immunomodulators, Anti-Inflammatory Agents, and Others), By Application (Oncology, Blood Disorders, Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Diabetes, and Others), By Manufacturing Type (Captive and Out-sourcing), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

August 2017 | 196 pages | ID: G9183431D70EN
Precision Business Insights (PBI)

Abstracts

Global Biosimilars Market Report Description:

Global biosimilars market report gives comprehensive outlook on biosimilars products across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on biosimilars market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application, manufacturing type, distribution channel, and geographic regions. This report studies biosimilars market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, biosimilars market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed biosimilars market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the biosimilars market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in manufacturing, supply and prescription of biosimilar products.

Global Biosimilars Market:

Global biosimilars market estimated to be valued US$ 4.10 Bn in 2017 and poised to grow at CAGR of 23.0% over 2017-2023. Market for biosimilars projected to reach US$ 14.23 Bn by 2023 owing to increasing patent expires of biologics and rising biosimilars product pipeline.

Growing demand for cost-effective medications to reduce healthcare burden is driving the market revenue growth

Global biosimilars market is gaining traction in recent times owing to its cost-effective pricing in comparison with patented or branded biologics, which are generally priced higher than biologics. The adoption of cost-effective biosimilars is rising in different healthcare setups across the developed and developing countries to curtail the growing pressure on healthcare budgets. The introduction of biosimilars has even led to improved access to the premium priced biopharmaceuticals in developing and under developed markets with lesser costs. Moreover, favorable government policies to promote cost-effective biosimilars expected to drive market revenue growth over the forecast period.

Increasing prevalence of several chronic diseases are expected to drive biosimilars market revenue growth over the forecast period

The rising prevalence of several chronic diseases such as cancer, diabetes, cardiovascular diseases, autoimmune disease, and among others across the developed and developing economies expected to drive the market for biosimilars over the forecast period. The growing demand from developing and underdeveloped market for improved healthcare access is driving the market revenue growth over the forecast period. Moreover, several players are increasing their focus form developed markets to developing markets to tap increasingly growing market opportunity is driving the market revenue growth. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide.

Europe emerged as prominent region for Biosimilars market across the globe

Europe market expected to hold the higher revenue share in global biosimilars market owing to healthcare practitioners shift to low priced drugs, and wider treatment choices available in the region. Asia-pacific biosimilars market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to large out-of-pocket healthcare expenditure and large medical unmet need due to lack of patented product availability.

COMPETITION ASSESSMENT

Key players profiles in the global Biosimilars market include:

• Amgen Inc. (U.S.)
• Biocon Ltd. (India)
• Celltrion, Inc. (South Korea)
• Dr. Reddy’s Laboratories Ltd. (India)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Pfizer Inc. (U.S.)
• Samsung Bioepis (South Korea)
• Novartis AG (Switzerland)
• Teva Pharmaceuticals Industries Ltd. (Israel)

Players in biosimilars market are focusing on introducing low-cost biosimilars in developed and developing economies to garner larger market revenue share in global biosimilars market. For instance, in 2015 Sandoz (Novartis AG) launched generic version (Glatopa) of copaxone (glatiramer acetate) in U.S. market.

KEY FINDINGS OF THE REPORT:

• Global Biosimilars market expanding at 23.0% CAGR over 2017 to 2023 to reach market value of US$ 14.23 Bn by 2023
• Based on application, oncology segment expected to emerge as larger revenue generating segment end of the forecast period owing to growing prevalence of the cancer
• Hospital pharmacies are prominent source for biosimilars drugs and accounted for larger market revenue share in 2016 expected to remain attractive over the forecast period
• Players are focusing on launching the newer biosimilars in the market to gain market revenue share

KEY FEATURES OF THE REPORT:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

DETAILED SEGMENTATION

By Products Type

• Monoclonal Antibodies
• Recombinant Hormones
• Recombinant Growth Factors
• Immunomodulators
• Anti-Inflammatory Agents
• Others

By Application

• Oncology
• Blood Disorders
• Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Diabetes
• Others

By Manufacturing Type

• Captive
• Out-sourcing

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• U.S
• Canada
• Europe
• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America
• Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

Contents

1. RESEARCH METHODOLOGY

1.1. Secondary and Primary research
  1.1.1. Secondary Sources
  1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms

2. SCOPE OF STUDY

2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study

3. EXECUTIVE SUMMARY

4. GLOBAL BIOSIMILARS MARKET DYNAMICS

4.1. Drivers
  4.1.1. Economic Drivers
  4.1.2. Demand Side Drivers
  4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends

5. UNIQUE FEATURES OF THE REPORT

5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis

6. GLOBAL BIOSIMILARS MARKET ANALYSIS, BY PRODUCTS TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Monoclonal Antibodies
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Recombinant Hormones
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Recombinant Growth Factors
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.4. Immunomodulators
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.5. Anti-Inflammatory Agents
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.6. Others
  6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. GLOBAL BIOSIMILARS MARKET ANALYSIS, BY APPLICATION TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Oncology
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Blood Disorders
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Autoimmune Diseases
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Growth Hormone Deficiency
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.5. Infectious Diseases
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.6. Diabetes
  7.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.7. Others
  7.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. GLOBAL BIOSIMILARS MARKET FORECAST, BY MANUFACTURING ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Captive
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Out-sourcing
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. GLOBAL BIOSIMILARS MARKET FORECAST, BY DISTRIBUTION CHANNEL ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Hospital Pharmacies
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.2. Retail Pharmacies
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.3. Online Pharmacies
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

10. BIOSIMILARS MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. North America Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.1.1. Products Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.1.1. Monoclonal Antibodies
    10.1.1.2. Recombinant Hormones
    10.1.1.3. Recombinant Growth Factors
    10.1.1.4. Immunomodulators
    10.1.1.5. Anti-Inflammatory Agents
    10.1.1.6. Others
  10.1.2. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.2.1. Oncology
    10.1.2.2. Blood Disorders
    10.1.2.3. Autoimmune Diseases
    10.1.2.4. Growth Hormone Deficiency
    10.1.2.5. Infectious Diseases
    10.1.2.6. Diabetes
    10.1.2.7. Others
  10.1.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.3.1. Captive
    10.1.3.2. Out-sourcing
  10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.4.1. Hospital Pharmacies
    10.1.4.2. Retail Pharmacies
    10.1.4.3. Online Pharmacies
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
10.2. Europe Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.2.1. Products Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.1.1. Monoclonal Antibodies
    10.2.1.2. Recombinant Hormones
    10.2.1.3. Recombinant Growth Factors
    10.2.1.4. Immunomodulators
    10.2.1.5. Anti-Inflammatory Agents
    10.2.1.6. Others
  10.2.2. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.2.1. Oncology
    10.2.2.2. Blood Disorders
    10.2.2.3. Autoimmune Diseases
    10.2.2.4. Growth Hormone Deficiency
    10.2.2.5. Infectious Diseases
    10.2.2.6. Diabetes
    10.2.2.7. Others
  10.2.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.3.1. Captive
    10.2.3.2. Out-sourcing
  10.2.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.4.1. Hospital Pharmacies
    10.2.4.2. Retail Pharmacies
    10.2.4.3. Online Pharmacies
  10.2.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.5.1. U.K
    10.2.5.2. Germany
    10.2.5.3. France
    10.2.5.4. Italy
    10.2.5.5. Spain
    10.2.5.6. Russia
    10.2.5.7. Poland 10.2.5.8. Rest of Europe
10.3. Asia-Pacific Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.3.1. Products Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.1.1. Monoclonal Antibodies
    10.3.1.2. Recombinant Hormones
    10.3.1.3. Recombinant Growth Factors
    10.3.1.4. Immunomodulators
    10.3.1.5. Anti-Inflammatory Agents
    10.3.1.6. Others
  10.3.2. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.2.1. Oncology
    10.3.2.2. Blood Disorders
    10.3.2.3. Autoimmune Diseases
    10.3.2.4. Growth Hormone Deficiency
    10.3.2.5. Infectious Diseases
    10.3.2.6. Diabetes
    10.3.2.7. Others
  10.3.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.3.1. Captive
    10.3.3.2. Out-sourcing
  10.3.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.4.1. Hospital Pharmacies
    10.3.4.2. Retail Pharmacies
    10.3.4.3. Online Pharmacies
  10.3.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.5.1. Japan
    10.3.5.2. China
    10.3.5.3. India
    10.3.5.4. ASEAN
    10.3.5.5. Australia & New Zealand 10.3.5.6. Rest of Asia-Pacific
10.4. Latin America Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.4.1. Products Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.1.1. Monoclonal Antibodies
    10.4.1.2. Recombinant Hormones
    10.4.1.3. Recombinant Growth Factors
    10.4.1.4. Immunomodulators
    10.4.1.5. Anti-Inflammatory Agents
    10.4.1.6. Others
  10.4.2. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.2.1. Oncology
    10.4.2.2. Blood Disorders
    10.4.2.3. Autoimmune Diseases
    10.4.2.4. Growth Hormone Deficiency
    10.4.2.5. Infectious Diseases
    10.4.2.6. Diabetes
    10.4.2.7. Others
  10.4.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.3.1. Captive
    10.4.3.2. Out-sourcing
  10.4.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.4.1. Hospital Pharmacies
    10.4.4.2. Retail Pharmacies
    10.4.4.3. Online Pharmacies
  10.4.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.5.1. Brazil
    10.4.5.2. Mexico
    10.4.5.3. Argentina
    10.4.5.4. Venezuela
    10.4.5.5. Rest of Latin America
10.5. Middle East & Africa (MEA) Biosimilars Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.5.1. Products Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.1.1. Monoclonal Antibodies
    10.5.1.2. Recombinant Hormones
    10.5.1.3. Recombinant Growth Factors
    10.5.1.4. Immunomodulators
    10.5.1.5. Anti-Inflammatory Agents
    10.5.1.6. Others
  10.5.2. Application Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.2.1. Oncology
    10.5.2.2. Blood Disorders
    10.5.2.3. Autoimmune Diseases
    10.5.2.4. Growth Hormone Deficiency
    10.5.2.5. Infectious Diseases
    10.5.2.6. Diabetes
    10.5.2.7. Others
  10.5.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.3.1. Captive
    10.5.3.2. Out-sourcing
  10.5.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.4.1. Hospital Pharmacies
    10.5.4.2. Retail Pharmacies
    10.5.4.3. Online Pharmacies
  10.5.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.5.1. Gulf Cooperation Council (GCC) Countries
    10.5.5.2. Israel
    10.5.5.3. South Africa
    10.5.5.4. Rest of MEA

11. COMPETITION LANDSCAPE

11.1. Strategic Dashboard of Top Market Players
11.2. Company Profiles (Introduction, Financial Analysis, Products & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  11.2.1. Amgen Inc. (U.S.)
  11.2.2. Biocon Ltd. (India)
  11.2.3. Celltrion, Inc. (South Korea)
  11.2.4. Dr. Reddy’s Laboratories Ltd. (India)
  11.2.5. F. Hoffmann-La Roche Ltd. (Switzerland)
  11.2.6. Pfizer Inc. (U.S.)
  11.2.7. Samsung Bioepis (South Korea)
  11.2.8. Novartis AG (Switzerland)
Teva Pharmaceuticals Industries Ltd. (Israel)